一个免疫特权位在食道癌中调解免疫疗法抵抗
Li Wan1,2, Boye Li3, Tianyun Ma4
1The Comprehensive Cancer Center, Department of Central Laboratory, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Journal for immunotherapy of cancer
|January 15, 2026
概括
在食道状细胞癌 (ESCC) 中的新辅助免疫疗法耐药性与免疫排除的瘤微环境有关. 准LAMC2+边界瘤细胞提供了一个有希望的策略来克服治疗失败.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 新辅助免疫疗法改善了食道状细胞癌 (ESCC) 治疗.
- 在ESCC不响应患者中免疫疗法耐药性的机制尚未完全理解.
- 空间瘤微环境在限制抗瘤免疫力的作用需要阐明.
研究的目的:
- 使用空间转录学绘制免疫景观的免疫疗法耐药ESCC.
- 确定ESCC治疗失败的细胞和分子驱动因素.
- 研究瘤微环境的空间结构与免疫疗法耐药性的关系.
主要方法:
- 空间转录组分析与大规模组织病理学相结合.
- 在免疫治疗耐药的ESCC中绘制免疫景观的空间结构.
- 确定治疗失败的细胞和分子决定因素.
主要成果:
- 在非响应者中观察到一种独特的免疫排除表型,具有周围瘤CD8+T细胞丰富和瘤内枯竭.
- 在侵袭前线的COL11A1+癌症相关纤维细胞 (CAF) 和SPP1+瘤相关巨细胞与免疫排除相关.
- 边界的LAMC2+瘤细胞,表现出改变的乳酸代谢和干性,通过Semaphorin 3C分泌组织这种免疫特权的利基,驱动CAF激活.
- 这种LAMC2+边界瘤细胞-免疫特权利基轴显示了泛癌与免疫治疗耐药性的相关性,确定了LAMC2作为预测生物标志物.
结论:
- 瘤侵入边缘是ESCC免疫疗法耐药性的关键决定因素.
- 定义免疫特权利基的空间标记和分子架构,为免疫排除障碍提供了洞察力.
- 对这一边界的治疗向是克服ESCC免疫疗法耐药性的有希望的策略.
相关概念视频
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


